Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
← catalyst calendarNCT07278479 · readout ≤ 773 d
Sponsored by Molecular Partners AG (industry) · MOLN — their whole pipeline →. With Orano Med LLC.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
138estimated
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-18 | actual | When the study began enrolling |
| Primary completion | Sep 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2032 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Large Cell Neuroendocrine Carcinoma
- Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)
- Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
- Small Cell Lung Cancer (SCLC)
- Gastroenteropancreatic NEC (GEP NEC)
- NEC of the Bladder
- Other DLL3 Expressing epNEC
Interventions
- Drug: [212Pb]Pb-MP0712 — also filed as [212Pb]Pb-DOTAM-MAM279
- Other: [203Pb]Pb-MP0712 — also filed as [203Pb]Pb-DOTAM-MAM279
Primary outcomes
what the primary-completion date above is the date OFTo assess incidence and severity of safety events following administration of [212Pb]Pb-DOTAM-MAM279
measured until 5 years after last dose
To assess dose modifications of [212Pb]Pb-DOTAM-MAM279
measured until 5 years after last dose
To estimate the maximum tolerated dose (MTD) and/or to define the recommended phase 2 dose (RP2D) for SCLC/LCNEC of the lung and epNECs
measured Phase 1, from start of treatment to end of first cycle (day 1 - 28)
To evaluate the preliminary anti-tumor activity of [212Pb]Pb-DOTAM-MAM279 in the dose expansion part
measured Phase 2a only; 12 months
Permalink · MOLN's whole pipeline · Catalyst calendar · Every registered study · What changed